Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that azathioprine may improve relapses and disability in patients with neuromyelitis optica spectrum disorder but is associated with higher adverse events compared to mycophenolate mofetil.

This paper suggests that ketoconazole 2% shampoo may enhance finasteride's effectiveness in treating androgenetic alopecia by more completely inhibiting the dihydrotestosterone pathway.

This correspondence discusses the treatment of alopecia universalis in a 6-year-old girl using simvastatin/ezetimibe, minoxidil, and prednisolone, but it reports no new clinical findings.

This study found that ursolic acid at 50 mg/kg improved biochemical, hormonal, and ovarian histopathological markers in a rat model of PCOS, suggesting its potential as a therapeutic option.

In this retrospective study, spironolactone improved acne in 86% of patients while showing minimal side effects, suggesting it as a safe treatment option for postadolescent acne with a low risk of short-term adverse effects like hyperkalemia.

The researchers reported that metabolism of progesterone to 3α,5α-THP in the hippocampus is important for its antiseizure effects in ovariectomized rats.

Results are not reported in the provided abstract, which issues an expression of concern regarding a 1997 article published in Gynecological Endocrinology.

In this study, short-term treatment with lovastatin showed no effect on symptom severity, prostate volume, or PSA levels in men with prostatic enlargement from presumed benign prostatic hyperplasia.

In this study, dexpanthenol exhibited antiepileptic and antidepressant-like effects in mice without impacting their motor coordination.

This report describes a case of SAPHO syndrome likely triggered by escalated dosing of infliximab in a 21-year-old woman, highlighting the complex nature of infliximab-induced adverse events, and suggesting a potential autoimmune basis involving two distinct pathophysiologies for SAPHO syndrome.

This abstract introduces TrichoFoam™, a new foaming vehicle for compounding pharmacies, designed to be a gentle, non-irritating option for alopecia treatment, acknowledging that current topical treatments are limited and oral products may cause adverse effects.

This systematic review explored the potential of cetirizine, an anti-inflammatory antihistamine, as a complementary treatment for androgenetic alopecia, reporting that it might help prevent hair follicle miniaturization by reducing inflammation and modulating immune activity, without notable side effects.

This review concludes that antiandrogens with ovarian suppression may significantly improve hirsutism and androgenetic alopecia in women with PCOS, but treatment needs to continue unless the underlying PCOS cause is addressed.

This review discusses fixed drug eruption (FDE) potentially linked to finasteride and emphasizes dermatologists' need to recognize its possible occurrence due to the drug's widespread use, but reports no new clinical results.

In this study, researchers observed that a topical gel containing 20% hypoxia mesenchymal stem cell secretome significantly reduced IL-15 and IFN-γ mRNA expression and baldness by 60% in male Wistar rats with fluconazole-related alopecia.

This study found that a 6-week taper of prednisone led to more than 25% hair regrowth in 30% to 47% of alopecia areata patients, and applying 2% topical minoxidil helped maintain this growth.

This review discusses existing literature on the effects of isoflavone in alleviating PCOS symptoms, highlighting its potential benefits in reducing testosterone levels, improving metabolic profiles, and lowering inflammation and oxidative stress, although findings have been both significant and non-significant.

In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.

This abstract contains fragmented and promotional text about various topics, including Hondrostrong and unrelated products, without presenting any new research findings.

This article reviews treatment strategies for polycystic ovary syndrome, specifically recommending letrozole for infertility, while also discussing lifestyle changes and other potential therapies, and reports no new research findings.

In this review, the authors found no evidence of harmful pregnancy outcomes from exposure to finasteride, and report that handling the medication poses negligible risk to a fetus.

This study found that both finasteride and flutamide effectively reduced hirsutism in women with polycystic ovary syndrome, decreasing the Ferriman-Gallwey score and hair diameter without significant side effects.

This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.

This review found that oral spironolactone is an effective and well-tolerated treatment for androgenic alopecia in women, especially when used with topical minoxidil, with generally minimal side effects reported.

Passiflora incarnata may help with anxiety and sleep issues but has side effects; teleconsultation for heart failure can improve quality of life; increased screen time for children during the pandemic led to more clinical complaints; older and severely affected COVID-19 patients are more likely to have long-term symptoms.

This study found that a 6-week course of prednisone may lead to more than 25% hair regrowth in up to 47% of patients with alopecia areata, with manageable side effects, while 2% topical minoxidil could reduce poststeroid hair loss.

This study found that while some patients with severe alopecia areata responded to high-dose prednisolone, the response was inconsistent and the therapy's risks prevent recommending it for general use.

This article discusses treatments for hirsutism and acne in women with polycystic ovary syndrome, suggesting that lower doses of current medications maintain efficacy while reducing cost and side effects, but reports no new clinical results.